Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup

Josée Bouchard1, Greene Shepherd2, Robert S. Hoffman3, Sophie Gosselin4,5,6, Darren M. Roberts7,8, Yi Li9, Thomas D. Nolin10, Valéry Lavergne1 and Marc Ghannoum1,11* on behalf of the EXTRIP workgroup

Abstract

Background: β-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and hypertension. Poisoning from BAAs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in BAAs poisoning.

Methods: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.

Results: A total of 76 studies (4 in vitro and 2 animal experiments, 1 pharmacokinetic simulation study, 37 pharmacokinetic studies on patients with end-stage kidney disease, and 32 case reports or case series) met inclusion criteria. Toxicokinetic or pharmacokinetic data were available on 334 patients (including 73 for atenolol, 54 for propranolol, and 17 for sotalol). For intermittent hemodialysis, atenolol, nadolol, practolol, and sotalol were assessed as dialyzable; acebutolol, bisoprolol, and metipranolol were assessed as moderately dialyzable; metoprolol and talinolol were considered slightly dialyzable; and betaaxiol, carvedilol, labetalol, mepindolol, propranolol, and timolol were considered not dialyzable. Data were available for clinical analysis on 37 BAA poisoned patients (including 9 patients for atenolol, 9 for propranolol, and 9 for sotalol), and no reliable comparison between the ECTR cohort and historical controls treated with standard care alone could be performed. The EXTRIP workgroup recommends against using ECTR for patients severely poisoned with propranolol (strong recommendation, very low quality evidence). The workgroup offered no recommendation for ECTR in patients severely poisoned with atenolol or sotalol because of apparent balance of risks and benefits, except for impaired kidney function in which ECTR is suggested (weak recommendation, very low quality of evidence). Indications for ECTR in patients with impaired kidney function include refractory bradycardia and hypotension for atenolol or sotalol poisoning, and recurrent torsade de pointes for sotalol. Although other BAAs were considered dialyzable, clinical data were too limited to develop recommendations.

Conclusions: BAAs have different properties affecting their removal by ECTR. The EXTRIP workgroup assessed propranolol as non-dialyzable. Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and...
Introduction
Poisoning from β-adrenergic antagonists (BAAs), also referred as β-blockers, can result in bradycardia, hypotension, dysrhythmias, and cardiogenic shock. Treatment is primarily supportive, but in severe cases high-dose insulin euglycemic therapy, vasopressors, and extracorporeal life support (ECLS) may be required. Extracorporeal treatments (ECTRs) are mentioned as part of the management of BAA poisoning, although their place remains uncertain and controversial [1]. The EXtracorporeal TReatments In Poisoning (EXTRIP) workgroup is composed of international experts representing diverse specialties and professional societies (Additional file 1). Its mission is to provide recommendations on the use of ECTR in poisoning (http://www.extrip-workgroup.org) [2–5]. We present EXTRIP’s systematic review and recommendations for the use of ECTR in patients with BAA poisoning.

Clinical pharmacology and toxicokinetics
BAAs are among the most commonly prescribed drugs for the prevention and treatment of cardiovascular disease [6, 7]. BAAs bind to β-adrenergic receptors, thereby competitively inhibiting the binding of epinephrine and norepinephrine to these receptors, and impairing conduction and contraction. Aside from their relatively small molecular size, BAAs have considerable heterogeneity regarding their physicochemical characteristics and pharmacokinetics (Table 1). For example, labetalol, propranolol, and carvedilol have a large volume of distribution, extensive protein binding, substantial hepatic metabolism, negligible renal clearance, and do not require dose modification in chronic kidney disease (CKD), whereas sotalol, nadolol, and atenolol have opposite characteristics. Additionally, their different properties influence their clinical effect; these include selectivity to the β-1 adrenergic receptors (e.g., metoprolol > propranolol), α-adrenergic antagonist activity (e.g., carvedilol, labetalol), intrinsic sympathomimetic activity (e.g., acebutolol, pindolol), membrane-stabilizing activity (MSA) from sodium channel blockade (e.g., propranolol, acebutolol, and labetalol), central nervous system (CNS) depression (e.g., propranolol), and Class III antidysrhythmic effect because of antagonism of potassium channels (e.g., sotalol). For several commercialized BAAs, intravenous and/or sustained-release forms are available.

In overdose, a prolonged absorption phase, saturation of enzymatic biotransformation, and poison-induced impairment of blood flow to organs may all contribute to a prolonged apparent elimination half-life, which has been described for propranolol [8], metoprolol [9, 10], atenolol [11], and sotalol [12–14] although this finding is inconsistent [15–18]. Protein binding does not appear to be modified in supratherapeutic concentrations [19, 20].

Overview of toxicity
Over the last 5 years, the number of BAA exposures reported to the United States National Poison Data System has increased [21], and is associated with 3.9% of fatal poisonings [21]. In 2019, 11,166 single ingredient BAA exposures were reported in the US including 19 fatalities [21]. Manifestations of BAA poisoning range from asymptomatic bradycardia to cardiogenic shock and death [22–25]. Cardiovascular symptoms usually appear within 2 h of ingestion and are unlikely to occur in an asymptomatic patient after 6 h from ingestion for immediate-release formulations [22, 26, 27], 8 h for sustained-release formulations, and 12 h for sotalol [12, 23, 24, 28]. Decreased consciousness and bronchospasm may occur after these periods, even with normal blood pressure and electrocardiogram [26, 29]. Other manifestations of poisoning from BAAs include hyperkalemia and hypoglycemia [30, 31]. Highly lipophilic drugs, like propranolol, penetrate the blood–brain barrier causing delirium, coma, and seizures [27, 30, 32, 33]. Sotalol, which also possesses potassium efflux channel blocking properties, causes QT interval prolongation and severe ventricular dysrhythmias, including torsade de pointes [12, 32, 34, 35]. In overdose, receptor selectivity is lost, leading to overlapping manifestations among BAAs [36, 37].

Some publications report a linear or threshold relationship between dose and outcome [32, 37]. For specific BAAs, a positive correlation was noted for propranolol [27, 32, 36], sotalol [32], atenolol [32], metoprolol [32, 38], carvedilol [39], and talinolol [36]. Unintentional exposures and inadvertent ingestions in young children rarely cause severe toxicity due to the smaller doses involved, although exceptions are reported [40, 41]. Quantification assays for BAAs are rarely available to guide clinical decisions, and concentrations correlate poorly with the development of symptoms [42–44], except for sotalol [45–48]. Fatalities from BAA ingestions are more likely if co-ingested with cardioactive drugs, such as calcium.
Table 1  Physicochemical properties and pharmacokinetics of immediate-release β-adrenergic antagonists

| Drug       | MW (Da) | Protein binding (%) | Protein binding | T<sub>MAX</sub> (h) | Endogenous T<sub>V1</sub> (h) | Endogenous CL (mL/min) | Renal CL (mL/min) | Therapeutic range (mg/L) | References |
|------------|---------|---------------------|-----------------|---------------------|-----------------------------|------------------------|-------------------|--------------------------|------------|
|            |         | Normal GFR CKD      | Normal GFR ESKD |                     |                             | Normal GFR ESKD        | Normal GFR ESKD   |                         |            |
| Acebutolol | 336     | 10–25               | 1.5–2.5         | N/A                 | 20–40                       | 600–800                | N/A               | 0.2–2                    | [19, 68, 69, 80, 138–148] |
| Alprenolol | 249     | 80–90               | 2.5–3.5         | N/A                 | 10–20                       | 800–1000               | N/A               | 0.03–0.15                | [149–152] [153] |
| Atenolol   | 266     | 0–5                 | 1.0–1.2         | 50–60               | 30–35                       | 140–180                | 20                | 0.1–1.5                  | [11, 20, 73, 79, 85, 90, 105, 118, 124, 148, 154–163] |
| Betaxolol  | 344     | 50                  | 4.5–6.0         | 5.0–6.5             | 75–90                       | 220–270                | 100–150           | 0.05–0.05                | [86, 148, 164–168] |
| Bisoprolol | 325     | 30                  | 2.0–3.0         | 90                  | 15–25                       | 200–250                | 50                | 0.01–0.1                 | [93, 98, 148, 169–175] |
| Bepindolol | 381     | N/A                 | 1.8–2.0         | N/A                 | 70                          | 350–400                | N/A               | 0.01–0.015               | [148, 176–180] |
| Cartelol   | 292     | 10–30               | 4                 | N/A                 | 8                          | 650                    | N/A               | 0.01–0.1                 | [148, 181–183] |
| Carvedilol | 405     | 98                  | 1.5–2.5         | N/A                 | 20–30                       | 600                    | 5                 | 0.02–0.2                 | [96, 148, 184–190] |
| Celiprolol | 379     | 25                  | 4–5              | N/A                 | 30–70                       | 900–1000               | N/A               | 0.05–0.5                 | [191–193] [148, 194–200] |
| Cetamolol  | 310     | N/A                 | 3.5              | N/A                 | 25–30                       | 420*                   | 150               | 0.01–0.1                 | [201–203] |
| Esmolol    | 295     | 55                  | 2.0–3.5         | Not applicable      | 0.2                         | 10,000–15,000         | 100–200           | 0.15–2                   | [95, 148, 204, 205] |
| Labetalol  | 328     | 50                  | 5.0–9.0         | 20–30               | 05–15                        | 1200–2000             | 20                | 0.03–0.3                 | [92, 206–212] [94, 148, 213] |
| Medroxalol | 372     | N/A                 | 10–15           | N/A                 | 30–50                       | 1000–1100              | N/A               | 0.07–0.007               | [88, 148, 216, 217] |
| Metipranol | 309     | 70                  | 3–4             | N/A                 | 40–50                       | 1100–1300             | N/A               | 0.02–0.1                 | [97, 148, 218–221] |
| Metoprolol | 267     | 10                  | 3.0–4.0         | N/A                 | 40–60                       | 800–1200              | 100               | 0.03–0.5                 | [222–225] [9, 73, 82, 106, 148, 226–230] |
| Nadolol    | 309     | 15–25               | 1.5–2.0         | N/A                 | 30                          | 120–250               | 30                | 0.01–0.25                | [75, 89, 148, 231–234] |
| Nebivolol  | 405     | 98                  | 9–12            | Variable            | 1–3                         | 800–1000              | 30                | 0.01–0.05                | [148, 235–241] |
| Oxprenolol | 265     | 80–85               | 0.8             | 35–50               | 05–15                        | 600–750               | 550               | 0.05–0.3                 | [84, 148, 242–252] |
| Penbutolol | 291     | 90–95               | 0.5–1.0         | N/A                 | 90                          | 300–600               | N/A               | 0.01–0.3                 | [253] [148, 254–262] |
| Pindolol   | 248     | 40–55               | 1.3–2.3         | 1.6–1.8             | 50–90                       | 450–550               | 180–240           | 0.02–0.15                | [148, 263–269] |
| Practolol  | 266     | 57                  | 1.5             | 90–100              | 2–5                         | 135                   | 20                | 1.5–5                    | [65, 67, 148, 270–274] |
| Premaeterol| 225     | 5                   | 2.5–3.5         | N/A                 | 25–35                       | 800–1400              | N/A               | 0.01–0.04                | [275–282] |
| Propranolol| 259     | 85–95               | 3.0–5.0         | 20–50               | 15–20                       | 800–1200              | 5                 | 0.02–0.3                 | [20, 66, 70, 74, 154, 230, 283–300] [73, 87, 131, 148, 301, 302] |
| Sotalol    | 272     | 0                   | 1.3–1.5         | 90                  | 25–35                       | 120–160               | 20–25             | 0.5–3                    | [71, 83, 303–307] [13, 15, 115, 148, 303, 306, 308–310] |
| Talinolol  | 363     | 60**                | 3.0–3.5         | 55                  | 25–35                       | 320–380               | 150–200           | 0.04–0.15                | [99, 104, 107, 148, 311–315] |
Table 1 (continued)

| Drug     | MW (Da) | Protein binding (%) | VD (L/kg) | F (%) | TMAX (h) | Endogenous T1/2 (h) | Endogenous CL (mL/min), Normal GFR | Renal CL (mL/min), Normal GFR | Therapeutic range (mg/L) | References |
|----------|---------|---------------------|-----------|-------|----------|--------------------|-----------------------------------|-------------------------------|------------------------|------------|
| Timolol  | 316     | 10                  | 2.0–2.5   | N/A   | 13–20    | 3–5                | 450–580                          | N/A                           | 0.005–0.1              | [300, 314–317] [72, 148, 315] |
| Tolamolol| 316     | 90                  | 1.2–1.8   | N/A   | 1–3      | 2–3                | 1100                             | N/A                          | N/A                    | [318–320]   |

MW: Molecular weight, VD: Volume of distribution, F: bioavailability, TMAX: Time to maximum concentration, T1/2: elimination half-life, CL: Clearance, N/A: Not available

* Not adjusted for bioavailability. ** No reference from primary data (taken from reviews)

& conflicting data, perhaps due to non-sensitive assays which included measurement of metabolites in early reports [68, 69]

Total body clearance and volume of distribution were obtained from intravenous data. If these data were unavailable but reported for oral data (i.e., as V/F or CL/F), then values were adjusted for bioavailability

This systematic review has taken the liberty to review all BAA's for which data exist, even if some are not currently commercially available
channel blockers [22, 32, 37, 49]. In cohorts of severe BAA poisoning, reported mortality rates range between 0 and 13% [21–23, 25, 32, 50–52].

Management of BAA poisoning is primarily supportive [1]. Although outside the scope of this review, standard care includes gastrointestinal decontamination, atropine, inotropes and vasopressors, temporary cardiac pacing, glucagon, intravenous calcium, high-dose euglycemic hyperinsulinemia, and extracorporeal life support (ECLS) [1, 53–57].

**Methods**

The workgroup developed recommendations following the EXTRIP methodology previously published [3] with modifications, updates, and clarifications. PRISMA statement was followed for reporting items of the presented systematic review of the literature. The full methods are presented in the online Additional file 1.

The search strategy used was as follows: [(dialysis or hemodialysis or haemodialysis or hemoperfusion or haemoperfusion or plasmapheresis or plasmapheresis or hemofiltration or hemofiltration or haemodiafiltration or haemodiafiltration or plasma exchange or CRRT or CVV* or CKRT or exchange transfusion) and (beta blockers or beta-adrenergic or acebutolol or alpenrolol or atenolol or betaxolol or bisoprolol or bopindol or carteolol or carvedilol or celiprolol or cetamolol or esmolol or labetalol or medroxalol or mepindol or metipranolol or metoprolol or nadolol or nebivolol or oxprenolol or pindolol or pindolol or practolol or prenalterol or pronanolol or sotalol or talindolol or timolol or tolamol)].

**Results**

Results of the literature search are presented in Fig. 1.

In the final analysis, 76 studies were included for qualitative analysis, including 4 in vitro experiments [58–61], 2 animal experiments [62, 63], 1 pharmacokinetic simulation study [64], 37 pharmacokinetic studies [65–101], and 32 case reports/series [13, 15, 35, 102–130]. No comparative studies or randomized controlled trials were identified.

**Summary of evidence**

**Dialyzability**

Because of the large heterogeneity in BAAs pharmacokinetics, no a priori overall estimation of dialyzability can be generalized for this entire drug class. Half-lives and clearances of BAAs obtained during ECTR are summarized in Table 2. Pharmacokinetic or toxicokinetic data related to ECTR were available for a total of 334 patients. Ninety percent of the pharmacokinetic articles were published prior to 1992. Although these older reports had robust methods, with several subjects and serial samplings of BAAs concentrations in blood and dialysate, they must be interpreted with caution as they may not reflect current hemodialysis technology. With improved blood and effluent flows and better catheters and filters, these data are expected to be more favorable. For example, atenolol clearance by ECTR has tripled in 30 years [78, 101], bisoprolol clearance has doubled in 20 years [98, 101], and nadolol clearance has increased by 50% in 5 years [75, 89].

When measured from dialysate collection, the amount of BAA removed divided by the reported ingested dose during hemodialysis (when adjusted for a 6-h treatment and bioavailability) was 24% for atenolol [101], 18% for bisoprolol [101], ∝0% for carvedilol [101], 0.5% for labetalol [92], 3.3% for metoprolol [101], 50% for practolol [67], ∝0% for propranolol [70], and 4.6% for talinolol [99].

Data for continuous kidney replacement therapy (CKRT) are sparse: in 3 cases of atenolol overdose, CKRT removed between 8 and 25% of total body burden adjusted for a 6-h period [120, 123, 128], with atenolol clearance ranging from 20 to 48 mL/min. In one sotalol overdose, CKRT clearance was estimated as 53 mL/min [122]. These clearances are considerably inferior to those achievable during high-efficiency intermittent hemodialysis (Table 2). There is limited evidence for hemoperfusion and therapeutic plasma exchange (TPE), which can remove BAAs with extensive protein binding. This appears true for propranolol in vitro [59, 61] and in vivo [102, 131], although its high volume of distribution and high hepatic clearance substantially limit its dialyzability. Hemoperfusion in 2 patients with talinolol overdoses yielded clearances of 100–120 mL/min [104, 107] but this represented <20% of ingested dose, due to its large volume of distribution. As for penbutolol, in vitro data show little to no effect from hemoperfusion and only a minor and slow effect from TPE [60]. For BAAs with limited protein binding, hemoperfusion would not be expected to surpass diffusive or convective techniques as confirmed in one case of metoprolol overdose in which measured clearance [106] was comparable to that obtained during hemodialysis [101]. As expected, dialyzability of BAAs by peritoneal dialysis was consistently poor, with inconsequential impact on pharmacokinetics, i.e., approximately 6% of atenolol was removed in 24 h [90], 0.1% of labetalol in 72 h [92], and the peritoneal clearance of betaxolol only represented 7.5% of total clearance [86].

An increase in serum/blood concentrations was often observed following ECTR, often referred as “rebound,” in both pharmacokinetic studies [67, 76, 83, 92] and toxicokinetic reports [13, 15, 105, 107, 115, 118, 124]. The
median increase in concentration was 15% and occurred independently of volume of distribution.

Table 3 presents grading of dialyzability with the level of evidence, as defined by EXTRIP criteria (Additional file 1). The grading and level of evidence for hemodialysis was assessed as: Dialyzable for atenolol, nadolol, practolol, and sotalol; Moderately dialyzable for acebutolol, bisoprolol, and metipranolol; Slightly dialyzable for metoprolol and talinolol; Not dialyzable for betaxolol, carvedilol, labetalol, mepindolol, propranolol, and timolol. Some publications report that metoprolol may be dialyzable based on achievable clearance of 80–120 mL/min [101]. However, this only represents a small proportion of total body clearance (regardless of genetic polymorphism of clearance pathways), resulting in removal of <10% of an ingested dose. Because of its high endogenous clearance and volume of distribution, propranolol will not be removed meaningfully by ECTR modalities.

Although extracorporeal clearance of BAAs is independent of kidney function, its relative impact compared to total body clearance will increase for some BAAs as kidney function declines. This can be illustrated graphically (Fig. 2): for example, a hemodialysis clearance of 120 mL/min will represent 46% of total clearance for atenolol in a patient with normal kidney function (endogenous clearance = 140 mL/min) compared to 86% in an anuric patient (endogenous clearance 20 mL/min). Comparatively, ECTR clearance will have very little impact on enhancing total clearance of propranolol, regardless of kidney function. These estimates are considered conservative for several BAAs including sotalol, practolol, nadolol, and betaxolol, as the ECTR data are at least 30 years old [67, 83, 86, 89]. Limited data exist for esmolol but even when assuming an optimal hemodialysis plasmatic clearance of 300 mL/min, this would represent less than 2% of total clearance [95].

Only 7 patients that could be assessed for dialyzability grading had normal kidney function, and only two reports were identified for a BAA (sotalol) whose grading may differ depending on kidney function [13, 15]. For these two cases, dialyzability was assessed as “Dialyzable” for one case of hemodialysis and “Moderately dialyzable” for one case of hemoperfusion-hemodialysis in series.

Clinical data
Among case reports and case series, the panel acknowledged variability in methodological quality and lack of reporting of critical information [132]. The evidence for a clinical effect of ECTR in BAA poisoning was available for 37 patients (acebutolol = 4, atenolol = 9, carvedilol = 1, metoprolol = 1, propranolol = 9, sotalol = 9, talinolol = 4), 16 of which had impaired kidney function (Table 4). All included patients were self-poisoned, except 6 dosing errors in end-stage kidney disease (ESKD) (atenolol = 1, sotalol = 5). Bradycardia and hypotension requiring vaso-pressors and/or inotropes were ubiquitous features for all BAAs except for propranolol and sotalol (predominant features for sotalol were ventricular dysrhythmias).

As reflected by changing trends in the management of BAA poisoning over almost 40 years, treatments were very heterogeneous. In particular, only eight patients
Table 2  Half-life and clearance of β-adrenergic antagonists during extracorporeal treatments

| Drug      | ECTR          | \(T_{1/2}\) (Hours) | Clearance (mL/min) | References |
|-----------|---------------|----------------------|--------------------|------------|
|           | During ECTR   | Endogenous          | Endogenous         |            |
|           | Median  n Range | Normal GFR ESKD     | Normal GFR ESKD    |            |
| Acetebutol| HD            | 6.1 (Met = 7.2) 7  2.2–7 | 4–10  45 (Met = 3.6) 12  30.5–55.1 | 600–800 N/A 68, 69, 80, 109, 113 |
|           | HF-HP         | 0.3 1                | 151               |            |
| Atenolol  | HD            | 4.6 48 0.5–17.8 5–8 | 50–100  119.5 25  18–31 1 | 140–180 20 73, 74, 78, 79, 85, 90, 91, 100, 101, 105, 116, 123, 124, 128 |
|           | CKRT          | 22 2 14.5–29.5      | 47 3 19.9–48      |            |
|           | HD-HP         | 3.4 1                | N/A               |            |
|           | PD            | 23 17 19.2–34       | 2.6 7 13.3–3.7    |            |
| Betaxolol | HD            | N/A 14–16 25–35     | 17.5 ± 0.7 12     | 220–270 100–150 86 |
|           | PD            | N/A                  | 11.7 ± 1.2 12     |            |
| Bisoprolol| HD            | 7.8 16 6.4–9.6 9–12 | 25–35 41.8 16 30.5–70 | 200–250 50 93, 98, 101 |
|           | PD            | 23.6 3 20.8–26.4    | N/A               |            |
| Carvedilol| HD            | 4.6 8 4.1–5.3 6–7  | 12.1 14 121–38.6 6 | 600 96, 101 |
| Esmolol   | HD            | 0.12 ± 0.1 6        | 0.2  Met = 76.8 ± 39.1 6 | 10,000–15,000 95 |
|           | PD            | 0.13 ± 0.1 6        | Met = 2.7 ± 0.5 6 |            |
| Labetalol | HD            | 1.8 7 0.6–3.8 3–10  | 10–12 37.4 14 25.7–97 | 1200–2000 92, 94 |
|           | PD            | 13.1 ± 6.3 8        | 1.9 ± 1.7 8       |            |
| Metipranol| HD            | 3.0 2 3–6            | 31 2 650 N/A      |            |
| Metipranol| HD            | 1.4 ± 0.5 8         | 2.5–3.0 N/A       | 1100–1300 N/A 97 |
| Metoprolol| HD            | 2.9 (Met = 5) 8     | 2.3–3 3–5 101 8 800–1200 73, 101, 106 |
|           | HP            | 2.2 1                | 96.1 1            |            |
| Nadolol   | HD            | 3.5 6 3.0–8.5 10–15 | 30–45 82 15 46.4–102 | 120–250 30 75, 89 |
| Oxprenolol| HD            | Met = 5.6 3         | 1–2  N/A 600–750 550 | 84 |
| Practolol | HD            | 14 (Met = 5) 14     | 8–30 10–13 60–80 >100% 6 135 20 65, 67 |
| Propranolol| HP            | 5.6 3 4.9–8.9 3–5  | 189 2 188–191 800–1200 66, 70, 73, 74, 87, 102 |
|           | HD            | 3.4 23 1.5–8        | 9.4 11 3.8–26.5 8 |            |
| TPE       | 1.2 1         | N/A                  |            |            |
| Sotalol   | HD            | 7 9 3.5–9.5 5–9  | 35–60 80 3 67–80 120–160 20–25 13, 15, 71, 83, 108, 115, 122 |
|           | HP-HD         | 2.8 1                | N/A               |            |
| Talinolol | HD            | N/A 10–12 20–25     | 28 7 320–380 109 |            |
|           | CKRT          | 18 1                 | 53.1 1            |            |
| Timolol   | HD            | 3.8 2 2.3–5.2 3–5  | 109 2 96–121     |            |
|           | HP            | 3.3 2 2.7–3.8       | 109 2 96–121     |            |

Legend: HD, Hemodialysis; HP, Hemoperfusion; HF, Hemofiltration; TPE, Therapeutic plasma exchange; PD, Peritoneal dialysis; CKRT, Continuous kidney replacement therapy; ECTR, Extracorporeal treatment; ESKD, End-stage kidney disease; Met, metabolite; GFR, Glomerular filtration rate; N/A, Not available; n, number

In order to make data consistent and comparable for analysis, some transformations were performed (if necessary): half-lives were calculated graphically; clearances were calculated from removal data; when both clearance from arterial-venous differences and dialysate collections were provided, these were averaged; in some cases, clearance reported by some authors were calculated by using blood flows and plasma concentrations which may lead to overestimations [13, 98, 109], and so were recalculated.

* Reported dialysate flow assumed to be > 300 mL/min
| Drug     | PK/TK grading          | Number of patients | Final grading and level of evidence   |
|----------|------------------------|--------------------|---------------------------------------|
|          |                        | HD: Dialyzable,    |                                       |
|          |                        | PD: Dialyzable,    |                                       |
|          |                        | CKRT: Slightly     |                                       |
|          |                        | dialyzable,       |                                       |
|          |                        | HP: Slightly       |                                       |
|          |                        | dialyzable,       |                                       |
|          |                        | Not dialyzable,    |                                       |
|          |                        |                   |                                       |
| Acebutolol | Dialyzable             | HD: Moderately    |                                       |
|          | Moderate dialyzable     | dialyzable,       |                                       |
|          | Slightly dialyzable     | dialyzable,       |                                       |
|          | Not dialyzable          | Not dialyzable,    |                                       |
| Atenolol  | Dialyzable              | HD: Dialyzable,    |                                       |
|          | Moderate dialyzable      | Slightly dialyzable|                                       |
|          | Slightly dialyzable      | Dialyzable,       |                                       |
|          | Not dialyzable          | Not dialyzable,    |                                       |
| Bisoprolol | Dialyzable              | HD: Moderately     |                                       |
|          | Moderate dialyzable      | dialyzable,       |                                       |
|          | Slightly dialyzable      | dialyzable,       |                                       |
|          | Not dialyzable          | Not dialyzable,    |                                       |
| Carvediol | Dialyzable              | HD: Not dialyzable,|                                       |
|          | Moderate dialyzable      | Not dialyzable,    |                                       |
|          | Slightly dialyzable      | Not dialyzable,    |                                       |
| Labetalol | Dialyzable              | HD: Not dialyzable,|                                       |
|          | Moderate dialyzable      | Not dialyzable,    |                                       |
|          | Slightly dialyzable      | Not dialyzable,    |                                       |
| Mepindolol | Dialyzable              | HD: Not dialyzable,|                                       |
|          | Moderate dialyzable      | Not dialyzable,    |                                       |
|          | Slightly dialyzable      | Not dialyzable,    |                                       |
| Metipranolol | Dialyzable            | HD: Moderately     |                                       |
|          | Moderate dialyzable      | dialyzable,       |                                       |
|          | Slightly dialyzable      | dialyzable,       |                                       |
| Metoprolol | Dialyzable              | HD: Slightly       |                                       |
|          | Moderate dialyzable      | dialyzable,       |                                       |
|          | Slightly dialyzable      | Not dialyzable,    |                                       |
| Nadolol   | Dialyzable              | HD: Dialyzable,    |                                       |
|          | Moderate dialyzable      | Not dialyzable,    |                                       |
|          | Slightly dialyzable      | Not dialyzable,    |                                       |
| Oxprenolol | Dialyzable              | HD (MET): Dialyzable,|                                    |
|          | Moderate dialyzable      | Not dialyzable,    |                                       |
|          | Slightly dialyzable      | Not dialyzable,    |                                       |
| Practolol | Dialyzable              | HD: Dialyzable,    |                                       |
|          | Moderate dialyzable      | Slightly dialyzable|                                       |
|          | Slightly dialyzable      | Not dialyzable,    |                                       |
|          | Not dialyzable          | Not dialyzable,    |                                       |
Table 3  (continued)

| Drug       | PK/TK grading | Number of patients | Final grading and level of evidence |
|------------|---------------|--------------------|-------------------------------------|
|            |               | HD | PD | CKRT | HP | TPE | HP-HD |
| Propranolol| Dialyzable    | 1, MET = 2 | | | | | |
|            | Moderately dialyzable | 2 | | | | | |
|            | Slightly dialyzable | | | | | | |
|            | Not dialyzable | | | | | | |
| Sotalol    | Dialyzable    | 6, 1 (Normal GFR) | | | | | |
|            | Moderately dialyzable | 1 | | | | | |
|            | Slightly dialyzable | | | | | | |
|            | Not dialyzable | | | | | | |
| Talinolol  | Dialyzable    | | | | | | |
|            | Moderately dialyzable | | | | | | |
|            | Slightly dialyzable | | | | | | |
|            | Not dialyzable | | | | | | |
| Timolol    | Dialyzable    | | | | | | |
|            | Moderately dialyzable | | | | | | |
|            | Slightly dialyzable | | | | | | |
|            | Not dialyzable | | | | | | |

MET, Metabolites; PK, Pharmacokinetics; TK, Toxicokinetics; HD, Hemodialysis; HP, Hemoperfusion; PD, Peritoneal dialysis; CKRT, Continuous kidney replacement therapy; TPE, Therapeutic plasma exchange; HD-HP, hemodialysis and hemoperfusion in series; GFR, Glomerular filtration rate

* 6 additional patients would be rated as “dialyzable” but the assay was non-specific and likely measured parent drug and metabolites, so the result is uninterpretable

** Based on half-life comparison, a criterion considered unreliable for poisons with a high Vd like propranolol, so not graded

![Fig. 2](image_url)

Proportion of hemodialysis clearance relative to total clearance. Legend: GFR: Glomerular filtration rate, ESKD: End-stage kidney disease, HD: Hemodialysis. *These are conservative estimations, as ECTR clearances would likely be higher if performed today. **based on endogenous clearance of 12,000 mL/min. For carvedilol, esmolol, propranolol, labetalol, talinolol, metoprolol, and acebutolol, it is assumed the ratio would apply regardless of kidney function
Table 4  Summary of clinical findings of patients receiving extracorporeal treatments for β-adrenergic antagonist removal

| Patient characteristics | Acebutolol (n = 4) | Atenolol (n = 9) | Carvedilol (n = 1) | Metoprolol (n = 1) | Propranolol (n = 9) | Sotalol (n = 9) | Talinolol (n = 4) |
|-------------------------|-------------------|------------------|--------------------|-------------------|-------------------|----------------|-----------------|
| Age, years              | 20 (17–27)        | 45 (28–74)       | 21                 | 49                | 31 (15–49)        | 66 (44–78)     | 21 (20–47)      |
| Men, %                  | 0                 | 56               | 0                  | 0                 | 44                | 78             | 50              |
| ESKD, %                 | 0                 | 11               | 0                  | 0                 | 0                 | 44             | 0               |
| Poisoning information   |                   |                  |                    |                   |                   |                |                 |
| Intentional overdose, % | 100               | 89               | 100                | 100               | 100               | 44             | 100             |
| Dose if acute ingestion, g | 8.4 (4.8–12) | 4.5 (2.5–10)     | 1.8               | 0.5               | 3.1 (0.6–5.0)     | 8.0 (7.2–14.4) | 2.5 (1.5–5.0)   |
| Peak concentration, mg/L | 14 (10–18)      | 14 (2.5–70)      | 0.6               | 2.8               | 1.5 (0.04–3)      | 17 (2.5–65)    | 5.5 (5.0–6.1)   |
| Time from ingestion to admission, hours | 2 (2–2)     | 6.5 (2–8)        | 0.8               | 0.8               | 2 (1–8)           | 2.5 (1–4)      | 6 (2–8)         |
| Signs/ Symptoms / Labs  |                   |                  |                    |                   |                   |                |                 |
| Coma, %                 | 100               | 89               | 100                | 100               | 50                | 100            | 75              |
| Altered consciousness, %| 100               | 100              | 100                | 100               | 83                | 100            | 75              |
| Bradycardia, %          | 100               | 100              | 100                | 100               | 100               | 100            | 100             |
| Severe dysrhythmia, %   | 25                | 0                | 100                | 0                 | 33                | 100            | 25              |
| Hypotension, %          | 100               | 100              | 100                | 100               | 75                | 89             | 100             |
| QRS complex duration, msec | 260          | 128 (98–160)     | N/A                | N/A               | 104               | 120 (104–140)  | 420             |
| Prolonged QRS complex duration, % | 100 | 43               | 0                 | 0                 | N/A               | 25             | 50              |
| QT interval duration, msec | N/A          | N/A              | 440 (400–448)     | N/A               | N/A               | 618 (509–880)  | 440             |
| Prolonged QT interval, % | N/A             | 17               | N/A                | N/A               | N/A               | 100            | 25              |
| Acute kidney injury, %  | 100               | 87.5             | 100                | 0                 | 0                 | 38             | 0               |
| Serum glucose, mmol/L   | 14.7             | 7.7 (2.2–19.2)   | 8.3                | N/A               | 10.7              | 4.4 (1.4–7.4)  | N/A             |
| Serum bicarbonate, mmol/L | 16              | 19 (10.8–21)     | N/A                | N/A               | 20 (15–25)        | 17             | N/A             |
| Serum lactate, mmol/L   | 1.9              | 4.6 (1.8–9.3)    | 4.7                | N/A               | 7.6 (1.9–13.2)    | 1.9            | N/A             |
| Serum potassium, mmol/L | 3.2              | 4.3 (<0.8–8.5)   | 5.9                | N/A               | 4.2 (3.7–4.7)     | 5.1 (3.8–7.1)  | N/A             |
| Other treatments        |                   |                  |                    |                   |                   |                |                 |
| Gastric lavage, %       | 25                | 44               | 0                  | 0                 | 67                | 22             | 75              |
| Activated charcoal, %   | 75                | 56               | 0                  | 100               | 50                | 11             | 25              |
| Vasopressors/ inotropes, % | 100         | 100              | 100                | 100               | 100               | 75             | 75              |
| Mechanical ventilation, % | 100          | 100              | 0                  | 100               | 17                | 75             | 75              |
| Atropine, %             | 100               | 56               | 0                  | 100               | 67                | 22             | 25              |
| Lipid emulsion, %       | 0                 | 11               | 0                  | 0                 | 16                | 0              | 0               |
| Pacemaker, %            | 100               | 44               | 100                | 100               | 33                | 88             | 50              |
| High-dose insulin euglycemic therapy, % | 0 | 67               | 0                  | 0                 | 33                | 0              | 0               |
| Glucagon, %             | 75                | 100              | 100                | 100               | 83                | 33             | 25              |
| Extracorporeal life support (ECLS), % | 25 | 22               | 100                | 0                  | 0                 | 0              | 0               |
| Extracorporeal treatments |                   |                  |                    |                   |                   |                |                 |
| Hemodialysis, n         | 1                 | 3                | 0                  | 0                 | 6                 | 0              | 0               |
| TPE, n                  | 0                 | 0                | 1                  | 0                 | 2                 | 0              | 0               |
| CKRT, n                 | 0                 | 3                | 0                  | 0                 | 0                 | 1              | 0               |
| More than 1 ECTR, n     | 0                 | 2                | 0                  | 0                 | 0                 | 0              | 0               |
| HF-HF, n                | 1                 | 0                | 0                  | 0                 | 0                 | 0              | 0               |
| HD-HF, n                | 1                 | 1                | 0                  | 0                 | 3                 | 1              | 1               |
| HF, n                   | 1                 | 0                | 0                  | 1                 | 4                 | 0              | 3               |
| Outcome                 |                   |                  |                    |                   |                   |                |                 |
| Death, %                | 0                 | 11               | 0                  | 0                 | 11                | 11             | 50              |
| Sequealae, %            | 25                | 11               | 0                  | 0                 | N/A               | 11             | N/A             |
| Length of stay, days    | 30 (7–49)         | 22 (12–32)       | 23                 | N/A               | 6 (5–32)          | 20             | N/A             |
| Length of ICU stay, days | 2 (2–2)        | 9.5 (1.5–28)     | 8                  | 3                 | 8.5 (4–13)        | 3 (2–6)        | N/A             |
| Length of life-threatening dysrhythmia | N/A | N/A            | N/A                | N/A               | N/A               | 56             | 16 (12–120)     |
| Length of prolonged QT interval, msec | N/A | N/A            | N/A                | N/A               | N/A               | N/A           | 37 (30–120)     |
| Length of bradycardia/hypotension, hours | 25 (24–26) | 48 (20–168)     | 120                | 18                | 67 (24–70)        | 36             | 9               |
received high-dose insulin euglycemic therapy and four patients received ECLS, treatments now considered likely to improve outcome [1]. For these reasons, it was difficult to determine a benefit from ECTR. Three patients died of cardiogenic shock [102, 103, 108], one of irreversible brain injury [107], and one of multiorgan failure after four weeks, despite marked improvement post-ECTR [105]. The overall mortality for the cohort was 13.5%.

For sotalol, resolution of dysrhythmias/torsade de pointes was rapid with intermittent hemodialysis, often occurring during or just after treatment [13, 15, 35, 115, 116, 121], while this was more protracted with slower techniques like peritoneal dialysis (PD) [114] or CKRT [122]. For atenolol (n = 9), when hemodialysis was used, an increase in blood pressure was noted after the first treatment, with one exception [129]. Again, apparent improvement was slower with CKRT [120, 127, 128]. Dysrhythmias recurred in two patients, within two hours of ECTR cessation, requiring another session [13, 15]. Although nine patients were reported for propranolol, the clinical impact of ECTR could only be analyzed in two patients: one improved slowly after hemoperfusion [125] while the other improved after TPE but had recurrence of hypotension shortly after [130]. For acebutolol, four patients were described, three of which improved during ECTR [109, 113, 117], while this was uncertain in one patient who received hemoperfusion [112]. In all four patients of talinolol poisoning, hemoperfusion was employed alone or in combination with hemodialysis, and two of them died [103, 107]. There was only one patient described for carvedilol [126] and metoprolol [106], which were difficult to interpret because of the co-ingested calcium channel blockers in both cases. No ECTR-associated complications were described in the cohort.

In summary, clinical improvement from ECTR was generally noted with BAAs considered dialyzable such as atenolol and sotalol when high-efficiency ECTRs were used, whereas this was questionable with other BAAs or when techniques with lower efficiency were used.

To further measure the effect of ECTR, outcomes of the ECTR cohort were compared to historical controls not receiving ECTRs (Table 5). Unfortunately, this analysis is severely hampered by the small numbers of reported patients, the variability in treatments provided and the heterogeneity of populations compared. For example, historical controls reported to poison control centers are expected to have more benign features than those included in the ECTR cohort. Overall, the mortality of patients receiving ECTRs for BAA poisoning was greater than those reported in historical controls, including one cohort of critically ill patients [23]. Aside from mortality, the only outcome that could be compared to assess the benefit of ECTR was the median duration of QT interval prolongation in sotalol poisoning, which was 37 h [IQR 33.5, 78.5] for the ECTR cohort (median maximal QTc interval = 140% of normal) versus 75 h [IQR 57, 87.5] in one historical cohort (median maximal QTc interval = 172%) [12]. However, this analysis is underpowered. With regard to harms and costs, the use of ECTR is associated with an increased risk of catheter-and ECTR-related complications and added costs which will vary depending on the choice of technique and the geographical location [133]. It is possible that ECTR may exacerbate hypotension in some cases despite the absence of net ultrafiltration, although the incidence of this risk and its magnitude are unknown.

Discussion
Recommendations
As per EXTRIP methods, the workgroup only voted on BAAs for which the number of patient clinical reports were sufficient. Although there were 4 reports for acebutolol and talinolol, they were not considered to be of sufficient quality to permit elaborations of recommendations.

General statements and indications for ECTR
Propranolol

- In patients severely poisoned with propranolol, we recommend against performing ECTR in addition to standard care rather than standard care alone (strong recommendation, very low quality evidence).

Atenolol

- In patients severely poisoned with atenolol and kidney impairment*, we suggest performing ECTR in addition to standard care rather than standard care alone when refractory bradycardia and hypotension is present (weak recommendation, very low quality evidence)
- In patients severely poisoned with atenolol and normal kidney function, we make no recommendation.
Table 5  Extracorporeal treatments + standard care versus standard care in β-adrenergic antagonists poisoning (evidence profile table)

| Drug assessment | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Summary of findings | Impact | Quality |
|-----------------|--------------|--------------|---------------|--------------|-------------|---------------------|---------------------|--------|--------|
| Mortality       |              |              |               |              |             |                     |                     |        |        |
| All β-adrenergic antagonists\(^n=10\) | Observational studies | Very serious\(^b\) | Not serious | Serious \(^c\) | Serious \(^d\) | Publication bias strongly suspected \(^g\) | ICU data 8.2% (9/110) admitted in 1 ICU 2002–9 [23] PCC and hospital data 3.8% (63/1678) 0/858: German PCC 2001–11 single substance [32] 1/11: children, self-harm [50] 2/73: 1 hospital 1993–7 [37] 0/40: 1 hospital 1996–80 [25] 4/280: 2 PCCs 1992–9 [22] 60/416: US PCCs 2017–19, at least major effect [21, 51, 52] | Comparable mortality between the ECTR group and the control group admitted to ICU (risk difference = 53 more deaths per 1000 patients in the ECTR group (with a 95% CI from 68 less to 175 more deaths per 1000) | ⬤◯◯◯ VERY LOW CRITICAL |
| Propranolol\(^f\) \(^n=5\) | Observational studies | Very serious\(^b\) | Not serious | Serious \(^c\) | Serious \(^d\) | Publication bias strongly suspected \(^g\) | 11.1% median dose 3.1 g (1/9) | Groups not comparable | ⬤◯◯◯ VERY LOW CRITICAL |
| Sotalol\(^g\) \(^n=3\) | Observational studies | Very serious\(^b\) | Not serious | Serious \(^c\) | Serious \(^d\) | Publication bias strongly suspected \(^g\) | 11.1% median dose 8.0 g (1/9) | Groups not comparable | ⬤◯◯◯ VERY LOW CRITICAL |
### Table 5 (continued)

| Quality assessment | Summary of findings | Importance |
|--------------------|--------------------|------------|
| **Drug** | **Study design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **ECTR + standard care** | **Standard care (controls)** | **Impact** | **Quality** | **Importance** |
| Atenolol<sup>a</sup>  
<sup>n</sup> = 3 | Observational studies | Very serious<sup>b</sup>  | Not serious<sup>c</sup> | Serious<sup>d</sup>  | Publication bias strongly suspected<sup>e</sup> | 11.1% median 4.5 g (1/9) | Overall = 0%  
0/48 German PCC 2001–11, single substance, median dose 0.5–0.8 g [32]  
0/10.1 hospital 1993–7 mean dose 2.0 g [37] | Groups not comparable | △△△△△ | VERY LOW | CRITICAL |

### Duration of QT interval prolongation

| Sotalol<sup>f</sup>  
<sup>n</sup> = 4 | Observational studies | Very serious<sup>b</sup>  | Not serious<sup>c</sup> | Serious<sup>d</sup>  | Publication bias strongly suspected<sup>e</sup> | Median = 3.7 h [3.3, 7.8] 3 pts, median 8 g | No formal comparison possible due to the small sample size of the ECTR group | △△△△△ | VERY LOW | IMPORTANT |

### Serious complications of catheter insertion<sup>l</sup>  
<sup>n</sup> = 5<sup>h</sup> | Observational studies | Not serious | Not serious<sup>1</sup>  | Not serious<sup>1</sup> | Not serious<sup>1</sup>  | Strong association<sup>1</sup> | Rate of serious complications of catheter insertion varies from 0.1% to 2.1% | ≈ 0 | Absolutef effect is estimated to be varying from 1 to 21 more serious complications per 1000 patients in the ECTR group | △△△△△ | MODERATE | CRITICAL |

### Serious complications of ECTR<sup>p</sup>  
<sup>n</sup> = 4<sup>i</sup> | Observational studies | Not serious | Not serious | Not serious | Strong association<sup>1</sup> | Rate of serious complications of ECTR varies according to the type of ECTR performed from 0.005% (IHD and CRRT), to 0.6% (TPE) and up to 1.9% (HP) | ≈ 0 | Absolutef effect is estimated to be varying from > 0 to 19 more serious complications per 1000 patients in the ECTR group depending of the type of ECTR performed | △△△△△ | MODERATE | CRITICAL |
“Requirement for extracorporeal life support,” “Length of requirement of vasopressors,” “Length of hospital stay,” “Length of ICU stay,” and “Sequelae” were outcomes ranked important or critical although no data were reported in the control group, so no comparison with the ECTR group could be performed.

Includes our systematic review of the literature on ECTR (37 patients from 32 case reports or case series) and 9 cohorts on standard care alone in β-adrenergic antagonists. No exclusion was based on the presence of co-ingestants or interventions.

Case reports published on effect of ECTR. Uncontrolled and unadjusted for confounders such as severity of poisoning, co-ingestions, supportive and standard care, and co-interventions. Confounding by indication is inevitable since ECTR was often attempted after other therapies had failed.

ECTR and standard care performed may not be generalizable to current practice (literature pre-dating 2000).

Few events in small sample size, optimal information size criteria not met.

Publication bias is strongly suspected due to the study design (case reports published in toxicology either report very severe poisoning with/without impressive recovery with treatments attempted).

Includes our systematic review of the literature on ECTR (9 case reports) and 4 cohorts on standard care alone in propranolol poisoning.

Includes our systematic review of the literature on ECTR (9 case reports) and 2 cohorts / case series on standard care alone in sotalol poisoning.

h) Includes our systematic review of the literature on ECTR (9 case reports) and 2 cohorts on standard care alone in atenolol poisoning.

i) Includes our systematic review of the literature on ECTR (3 case reports) and 1 case series on standard care alone in sotalol poisoning.

For venous catheter insertion: serious complications include hemothorax, pneumothorax, hemomediastinum, hydromediastinum, hydrothorax, subcutaneous emphysema, retroperitoneal hemorrhage, embolism, nerve injury, arteriovenous fistula, tamponade, and death. Hematoma and arterial puncture were judged not serious and thus excluded from this composite outcome. Deep venous thrombosis and infection complications were not included considering the short duration of catheter use.

Based 5 single-arm observational studies: 2 meta-analyses comparing serious mechanical complications associated with catheterization using or not an ultrasound, which included 6 RCTs in subclavian veins [322] and 11 in internal jugular veins [323]; 2 RCTs comparing major mechanical complications of different sites of catheterization [324, 325]; one large multicenter cohort study reporting all mechanical complications associated with catheterization [326]. Rare events were reported from case series and case reports.

Not rated down for inconsistency since heterogeneity was mainly explained by variation in site of insertion, use of ultrasound, experience of the operator, populations (adults and pediatric), urgency of catheter insertion, practice patterns, and methodological quality of studies.

Not rated down for indirectness since cannulation and catheter insertion was judged similar to the procedure for other indications.

Not rated down for imprecision since wide range reported explained by inconsistency.

The events in the control group are assumed to be zero (since no catheter is installed for ECTR); therefore, the magnitude of effect is at least expected to be large, which increases the confidence in the estimate of effect. Furthermore, none of the studies reported 95%CI which included the null value and all observed complications occurred in a very short timeframe (i.e., few hours).

For IHD and CKRT: serious complications (air emboli, shock, and death) are exceedingly rare. Minor bleeding from heparin, transient hypotension, and electrolytes imbalance were judged not serious. For HP, serious complications include severe thrombocytopenia, major bleeding, and hemolysis. Transient hypotension, hypoglycemia, hypocalcemia, and thrombocytopenia were judged not serious. For TPE, serious complications include citrate toxicity, severe allergic reaction, anaphylaxis, and vasovagal reaction. Hypotension, hypocalcemia, and urticaria were judged as not serious. All non-serious complications were excluded from this composite outcome.

IHD/CKRT: Based on 2 single-arm studies describing severe adverse events per 1000 treatments in large cohorts of patients [327, 328]. TPE: based on the 2 most recent one-arm studies reporting potential life-threatening adverse events [329, 330]. HP: based on 2 small single-arm studies in poisoned patients [331, 332]. Rare events were reported in case series and case reports.

Assuming that patients in the control group would not receive any form of ECTR, the events in the control group would be zero; therefore, the magnitude of effect is at least expected to be large, which increases the confidence in the estimate of effect. Furthermore, none of the studies reported 95%CI which included the null value and all observed complications occurred in a very short timeframe (i.e., few hours).
for or against performing ECTR in addition to standard care rather than standard care alone (no recommendation, very low quality evidence)

**Sotalol**

- In patients severely poisoned with sotalol and kidney impairment*, we suggest performing ECTR in addition to standard care rather than standard care alone when refractory bradycardia and hypotension and/or recurrent torsades de pointes is present (weak recommendation, very low quality of evidence)
- In patients severely poisoned with sotalol with normal kidney function, we make no recommendation for or against performing ECTR in addition to standard care rather than standard care alone (no recommendation, very low quality evidence).
- In patients severely poisoned with sotalol, we suggest against performing ECTR solely based on the QT interval (weak recommendation, very low quality evidence).

*“Kidney impairment” was defined as stage 3B, 4, or 5 CKD (i.e., eGFR < 45 mL/min/1.73m²) or AKI as KDIGO stage 2 or 3 AKI. In the absence of a baseline serum creatinine concentration, kidney impairment was defined as an eGFR < 45 mL/min/1.73m² in adults; and in children with no baseline creatinine, the use of KDIGO criteria of AKI stage 2 and 3 after imputing a baseline serum creatinine using the Schwartz 2009 formula assuming 120 mL/min/1.73m² of “normal” eGFR. The presence of oligoanuria unresponsive to fluid resuscitation should be considered as impaired kidney function, regardless of serum creatinine concentration (See supplemental section).

**Rationale**

Severe BAA poisoning can lead to bradycardia and hypotension refractory to vasopressors and inotropes, occasionally causing death [57]. Assuming all other priority therapeutic measures are in place to mitigate BAA toxicity including involvement of a clinical toxicologist, the workgroup considered the use of ECTR for severe poisoning due to propranolol, atenolol, and sotalol.

Propranolol has a short half-life and a high endogenous clearance independent of kidney function. These attributes added to extensive protein binding make this drug non-dialyzable regardless of the ECTR used. Although the data were limited, ECTR did not appear to accelerate clinical recovery and the mortality from ECTR cases was higher than historical controls. For these reasons, the workgroup recommended against ECTR for propranolol poisoning (Median: 1.0/Upper quartile: 1.0/Disagreement index: 0.0).

Atenolol and sotalol both have endogenous clearances (and elimination half-lives) that are highly dependent on kidney function. The contribution of ECTR in patients with kidney impairment is considerable. The greater the impairment in kidney function, the greater the relative toxicokinetic effect of ECTR. Both are considered to be “Dialyzable” in patients with kidney impairment. Although the number of cases is small, clinical improvement from sotalol and atenolol poisoning appears to coincide with initiation of ECTR, especially when high efficiency techniques are used. It is conceivable that relevant patient-important outcomes (PIOs), such as length of vasopressor requirement, long-term sequelae, and mortality would be reduced with ECTR in this population. In patients who already have vascular access in place, the risk associated with insertion is already taken into account, so the risk-benefit ratio is even lower. The workgroup suggested ECTR in patients with impaired kidney function for both atenolol (Median: 7.0 / Lower quartile: 4.0 / Disagreement index: 0.59) and sotalol (Median: 7.0 / Lower quartile: 4.0 / Disagreement index: 0.59); the workgroup nevertheless acknowledged that the initiation of ECTR, even without net ultrafiltration, might exacerbate hemodynamic instability and may not be possible to perform. The benefit of ECTR is theoretically less for patients poisoned with atenolol or sotalol and normal kidney function, even if the addition of ECTR can approximately double total clearance; the duration of toxicity is expected to be much shorter in this population. For these reasons, the workgroup considered that, at the time of writing, the benefits and harms were balanced with considerable knowledge gaps and made no recommendation for patients poisoned with atenolol or sotalol and normal kidney function.

A major consideration for sotalol is its ability to cause QT prolongation, which is uncommon with other BAAs and can lead to life-endangering torsades de pointes, a poor prognostic indicator in sotalol poisoning. Obviously, the workgroup is not advocating ECTR for the treatment of torsades de pointes, as ECTR would not be technically feasible. However, recurrent torsades de pointes is indicative of severity and of a role for ECTR initiation. For non-recurrent torsades, ECTR is not justified. In the literature, there is no clear QTc duration cutoff which predicts torsade de pointes [134]. The risk of life-threatening cardiac events increases as the QTc gets longer than 500 ms [134, 135] and each 10-ms increase contributes to approximately a 5% to 7% exponential increase in risk. However, QTc can be prolonged at therapeutic sotalol concentration. These findings support the recommendation of the workgroup not to perform ECTR solely based on QT prolongation.
Although monitoring of poison concentrations is useful in some settings, there remain too many uncertainties in the concentration-effect relationship to provide a threshold concentration for ECTR initiation in BAA poisoning. Hypotension and bradycardia are poorly related to atenolol concentrations \[136\], QT interval prolongation is correlated with sotalol concentrations but with considerable imprecision \[45–48\]. Further, only 7 out of 37 panelists had access to atenolol or sotalol assays and only 3 within 12 hours of it being ordered. Very few clinicians outside of large academic centers are likely to have access to BAA assays. The panel did recognize the value of a subtherapeutic concentration in excluding the need for ECTR. The panel emphasized that the indication for ECTR is likely to depend on the availability of ECLS, which should be instituted prior to ECTR assuming both are available in the same center, as it is simple to add a hemodialysis circuit to extracorporeal membrane oxygenation.

**Research gaps**

Additional pharmacokinetic data in ESKD patients are needed, especially during hemodialysis, for acebutolol (because of imprecision about sampling in studies), betaxolol, bopindolol, carteolol, cetamolol, nadolol, oxprenolol, pindolol, sotalol, and timolol. In addition, clinical cases of poisoning with toxicokinetic data of ECTR is required for acebutolol, atenolol, bisoprolol, metoprolol, nadolol and sotalol in patients with normal GFR or slightly impaired GFR.

Toxicokinetic/toxicodynamic relationships should better evaluate if serum concentrations can determine the utility of ECTR in clinical decision-making. Better prognostic markers on admission would also be useful to determine which subset of patients are most likely to benefit from ECTR.

The added value of ECTR to ECLS should be demonstrated. In patients with impaired kidney function, additional studies could help characterize if the transfer of an unstable patient for ECTR with or without ECLS could potentially be beneficial and within which timeframe this could be useful. If ECLS is unavailable in the initial center, studies could compare clinical outcomes associated with transfer for ECLS vs. hemodialysis alone at the initial center.

**Type of ECTR**

In patients severely poisoned with atenolol or sotalol requiring ECTR: when all modalities are available, we recommend using intermittent hemodialysis rather than any other type of ECTR (strong recommendation, very low quality evidence).

**Rationale**

If ECTR is used for poison removal, then the most efficient modality at removing atenolol or sotalol should be selected, i.e., intermittent hemodialysis. In the rare circumstance that intermittent hemodialysis is unavailable but other techniques are, then hemoperfusion, CKRT, sustained low-efficiency dialysis (SLED), or prolonged intermittent renal replacement therapy (PIRRT) can be used, preferably the modality providing the best solute clearance and quickest to deliver. Although CKRT and other “slower” techniques such as SLED/PIRRT are often preferred for patients with hemodynamic compromise, this applies specifically to those requiring net ultrafiltration. It is therefore uncertain if CKRT or SLED/PIRRT would be better tolerated than intermittent hemodialysis in patients not requiring net ultrafiltration. It is acknowledged that all techniques may exacerbate hypotension to some extent for various causes including fluid and solute shifts, and electrolyte fluxes.

Regardless of technique, ECTR parameters should be optimized to enhance clearance (higher blood and effluent flows, filter/dialyzer with larger surface area) \[137\] and to reduce risk of hemodynamic compromise (priming of the ECTR circuit, lowering dialysate temperature, dialysate/replacement fluid without low potassium, calcium and magnesium concentrations, and minimizing net ultrafiltration).

Importantly, if dialysis is performed for sotalol poisoning, the input of a nephrologist is recommended to ensure that the serum magnesium concentration remains above 1 mmol/L and serum potassium concentration within 4.5-5 mmol/L to minimize the risk of dysrhythmias, including torsade de pointes. Magnesium may be added to the dialysate or administered intravenously to offset its elimination during ECTR.

**Research gap**

Data with hemoperfusion and high-cut off dialysis should be assessed in poisoning from highly protein-bound BAAs with reasonably low volume of distribution and plasma clearance such as penbutolol, oxprenolol, and carvedilol.

**Cessation of ECTR**

In patients severely poisoned with atenolol or sotalol requiring ECTR, we recommend stopping ECTR based on clinical improvement (strong recommendation, very low quality of evidence).
Rationale

The indication to stop ECTR, once initiated, should be reliant on clinical indicators of improvement. These include appropriate heart rate and blood pressure for adequate end organ perfusion, weaning of ECLS, decreasing inotropic and vasopressor requirements, and sustained cessation of torsade de points if applicable. It is recognized that QT interval prolongation may persist even at therapeutic sotalol concentrations so the use of this target for cessation is not recommended. In addition, there is no predefined duration of ECTR to treat BAA poisoning as this will depend on the type and amount of BAA ingested, as well as the underlying kidney function in some cases. The workgroup suggested not to cease ECTR solely based on a target serum concentration, as safe thresholds are not well known, and assays are infrequently available to guide judgement.

Our work has several strengths. This is the first systematic review of the use of extracorporeal therapy in BAA poisoning. This systematic review summarizes the best evidence on the use of extracorporeal therapy in BAA poisoning using the most stringent guideline methodology (GRADE). No articles were rejected based on language or year of publication. It also provides clinical recommendations following a voting process using a two-round modified Delphi procedure from an international collaborative comprising recognized experts from various clinical specialties and resource settings. Limitations of the study are inherently associated with the quality of articles used for the drafting of recommendations. In many cases, details regarding these articles were of poor quality. There were insufficient data to draft recommendations on BAAs other than propranolol, atenolol, and sotalol due to the limited published evidence available; however, the workgroup acknowledged there was little clinical plausibility of a clinical benefit from ECTR for non-dialyzable BAAs such as betaxolol, carvedilol, esmolol, labetalol, mepindolol, and timolol.

Conclusion

In conclusion, poisoning from BAAs can cause serious toxicity and death. β-adrenergic antagonists have different physicochemical properties and pharmacokinetics which will affect their removal by ECTR. The EXTRIP workgroup assessed propranolol as non-dialyzable. Atenolol as well as sotalol were assessed as dialyzable in patients with kidney impairment and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present.

Abbreviations

BAA: Beta-adrenergic antagonists; CKD: Chronic kidney disease; CKRT: Continuous kidney replacement therapy; CI: Clearance; ECLS: Extracorporeal life support; ECTR: Extracorporeal treatments; ESKD: End-stage kidney disease; EXTRIP: The Extracorporeal Treatments In Poisoning workgroup; F: Bioavailability; GFR: Glomerular filtration rate; HD: Hemodialysis; HF: Hemofiltration; HP: Hemoperfusion; ICU: Intensive care unit; IHD: Intermittent hemodialysis; IQR: Interquartile range; Met: Metabolite; MW: Molecular weight; N/A: Not available; PCC: Poison control center; PD: Peritoneal dialysis; PII: Patient-important outcomes; PK: Pharmacokinetics; Pts: Patients; T1/2: Elimination half-life; TK: Toxicokinetics; T_max: Time to maximum concentration; TPE: Therapeutic plasma exchange; V_d: Volume of distribution.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13054-021-03585-7.

Acknowledgements

We would like to acknowledge the valuable help of our dedicated translators, librarian, data extractors, and meeting secretary. Official translators were Alexandra Angulo, Alla Abbott, Anant Vipat, Andreas Betz, Angelina Kovaleva, Denise Gemmellaro, Ewa Brodziuk, Helen Johnson, Junzheng Peng, Marcela Covic, Nathalie Eckhout, Rosie Finnegan, Sahil Topal, and Vilma Erchard. The librarian was Elena Guadagno. Data extractors for EXTRIP-2 included Maria Rif, François Filion, Karine Mardini, Maria Rif, Tudor Botnaru, Elizabeth Koo, and Gabrielle Wilson. The meeting secretary was Brenda Gallant.

In addition to the authors of this manuscript, members of the EXTRIP Group include: Badria Alhatali, Kurt Anseeuw, Steven Bird, Ingrid Berling, Timothy E Bunchman Diane P Cailello, Paul K Chin, Kent Dho, Tais Galvao, David S Goldfarb, Hossein Hassanian-Moghaddam, Lotte CG Hoeberg, Siba Kallab, Sofia Kebede, Jan T Kielstein, Andrew Lewington, Etienne M Macedo, Rob MacLaren, Bruno Megarbane, James B Mowry, Thomas D Nolin, Marlies E Ostermann, Ai Peng, Jean-Philippe Roy, Anitha Vijayan, Steven J Walsh, Anselm Wong, David M Wood, Christopher Yates, Josée Bouchard, Greene Shepherd, Robert S. Hoffman, Sophie Gosselin, Darren M. Roberts, Yi Li, Thomas D. Nolin, Valéry Lavergne and Marc Ghanourni.

Authors’ contributions

MG, SG, RSH, VL, TSN, YL, and DMR designed the study; JB, MG, and GS, carried out extractions; all authors participated in analysis and interpretation of data; JB, MG, GS, and VL made the tables and figures; all authors drafted and revised the paper; all authors provided intellectual content of critical importance to the work. All authors read and approved the final manuscript.

Funding

EXTRIP received support consisting of an unrestricted grant of $60,633 Canadian from the Verdun Research Fund (the institution of Marc Ghannoun) solely for the reimbursement of travel expenses for the in-person guideline meeting and payment to dedicated translators for retrieval and translation of foreign language articles. The funding source did not have a role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The data underlying this article will be shared on reasonable request to the corresponding author.

Declarations

Ethics approval and consent to participate

Not applicable.
Consent for publication
Not applicable.

Competing interests
TDN reports personal fees from MediBeacon, CytoSorbents, and McGaw-Hill Education outside the submitted work. MG is a scholar of the Fonds de Recherche du Québec—Santé. DMR acknowledges support of St. Vincent’s Centre for Applied Medical Research Clinician “Buy-Out” Program. AV reports consulting functions for NxStage, Astute Medical, and Boehringer-Ingelheim Centre for Applied Medical Research. DMR acknowledges support of St. Vincent’s Hospital, Pittsburgh, PA, USA. 11 Verdun Hospital, 4000 Lasalle Boulevard, Verdun, Montreal, QC, Canada. 12 Department of Pharmacy and Therapeutics, and Department of Medicine, New York, NY, USA. 13 Department of Emergency Medicine, McGill University, Montreal, QC, Canada. 14 Centre Antipoison du Québec, Quebec, QC, Canada. 15 Departments of Renal Medicine and Transplantation and Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, NSW, Australia. 16 St. Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia. 17 Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. 18 Department of Pharmacy and Therapeutics, and Department of Medicine Renal-Electrolyte Division, University of Pittsburgh Schools of Pharmacy and Medicine, Pittsburgh, PA, USA. 19 Verdun Hospital, 4000 Lasalle Boulevard, Verdun, Montreal, QC, H4G 2A3, Canada.

Author details
1 Research Center, CRIUSS du Nord-de-l’Île-de-Montréal, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, QC, Canada. 2 Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA. 3 Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, NYU Grossman School of Medicine, New York, NY, USA. 4 Centre Intégré de Santé et de Services Sociaux (CISSS) Montérégie-Centre Emergency Department, Hôpital Charles-Lemoyne, Greenfield Park, QC, Canada. 5 Department of Emergency Medicine, McGill University, Montreal, QC, Canada. 6 Centre Antipoison du Québec, Quebec, QC, Canada. 7 Departments of Renal Medicine and Transplantation and Clinical Pharmacology and Toxicology, St. Vincent’s Hospital, Sydney, NSW, Australia. 8 St. Vincent’s Clinical School, University of New South Wales, Sydney, NSW, Australia. 9 Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. 10 Department of Pharmacy and Therapeutics, and Department of Medicine Renal-Electrolyte Division, University of Pittsburgh Schools of Pharmacy and Medicine, Pittsburgh, PA, USA. 11 Verdun Hospital, 4000 Lasalle Boulevard, Verdun, Montreal, QC, H4G 2A3, Canada.

Received: 1 March 2021 Accepted: 26 April 2021
Published online: 10 June 2021

References
1. Rotella JA, Greene SL, Koutsogiannis Z, Graudins A, Hung Leang Y, Kuan K, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila). 2020;1–41.
2. Ghannoum M, Nolin TD, Lavergne V, Hoffman RS. Blood purification in toxicology: nephology’s ugly duckling. Adv Chronic Kidney Dis. 2011;18(3):160–6.
3. Lavergne V, Nolin TD, Hoffman RS, Robert D, Gosselin S, Goldfarb DS, et al. The EXTRIP (Extracorporeal Treatments In Poisoning) workgroup: Guideline methodology. Clin Toxicol. 2012;50:403–13.
4. Berling I, King JD, Shepherd G, Hoffman RS, Alhatli B, Lavergne V, et al. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. J Am Soc Nephrol. 2020;31(10):2475–89.
5. Wong A, Hoffman RS, Walsh SJ, Roberts DM, Gosselin S, Bunchman TE, et al. Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2021;1–31.
6. The 50 most commonly prescribed drugs in America and their average prescribed- drugs-in-ameri ca/. https://www.drugreport.com/50-commonly-prescribed-drugs-in-america/.
7. WHO. WHO Model Lists of Essential Medicines 2019 [Available from: https://www.who.int/medicines/publications/essentialmedicines/en/]
8. Ducrot F, Zech P, Perrot D, Moskovtchenko JF, Traeger J. Deliberate self-overdose with propranolol: Changes in serum levels. Nouv Presse Med. 1978;7(11):27–8.
9. Isbister GK, Ang K, Gorman K, Cooper J, Mostafa A, Roberts MS. Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. Clin Toxicol. 2016;54(9):881–5.
10. Grass J, Steinwall J, Lindeman E. Prolonged elimination after massive overdose of metoprolol and amiodipine in a patient treated with extracorporeal life support (ECLS). Clin Toxicol (Phila). 2018;56(6):528–9.
11. Snook CP, Sigvardsdottir K, Kristinsdottir J. Severe atenolol and diltiazem overdose. J Toxicol Clin Toxicol. 2000;38(6):661–5.
12. Neuvonen PJ, Etonen E, Vuorenmaa T, Laasko M. Prolonged QT interval and severe tachyarrhythmias: common features in patients with sotalol overdosage. Clin Pharmacol Ther. 1981;29(2):268.
13. Singh SN, Lazio A, Cohen A, Johnson M, Fletcher RD. Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy. Am Heart J. 1991;121(2 Pt 1):601–2.
14. Gustavsson CG, Vinge S, Norlander BO, Pantev E. Pharmacokinetic evaluation of a case of massive sotalol intoxication. Ann Pharmacother. 1997;31(7–8):856–9.
15. Miethe R, Habel U, Schuster HP. Sotalol self-poisoning treated with hemoperfusion/hemodialysis. Intensivmedizin und Notfallmedizin. 1996;33(1):47–51.
16. DeLima LGP, Kharasch ED, Butler S. Successful pharmacologic treat- ment of massive atenolol overdose: sequential hemodynamics and plasma atenolol concentrations. Anesthesiology. 1995;83(1):204–7.
17. Freestone S, Thomas HM, Bharma RK, Dyson EH. Severe atenolol poisoning: treatment with prenilatril. Hum Toxicol. 1986;5(5):343–5.
18. Page C, Hackett LP, Isbister GK. The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report. J Med Toxicol. 2009;5(3):139–43.
19. Meffin PJ, Winkle RA, Peters FA, Harrison DC. Acetobutolol disposition after intravenous administration. Clin Pharmacol Ther. 1977;22(5 Pt 1):557–67.
20. Barber HE, Hawksworth GM, Kitteringham NR, Petersen J, Petrie JC, Swann JM. Protein binding of atenolol and propranolol to human serum albumin and in human plasma [proceedings]. Br J Clin Pharmacol. 1978;6(5):446P–P447.
21. Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Brooks DE, Dibert KW, et al. 2019 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila). 2020;58(12):1360–541.
22. Love JN, Howell JM, Litovitz TL, Klein-Schwartz W. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000;38(3):275–81.
23. Megarbane B, Deye N, Malissin I, Baud FJ. Usefulness of the serum lactate concentration for predicting mortality in acute beta-blocker poisoning. Clin Toxicol. 2010;48(10):974–8.
24. Hermanns-Clausen M, Desel H. Sotalol overdose: how dangerous is it? Clin Toxicol. 2002;40:350.
25. Elkharrat D, Bismuth C. Acute intoxication by beta-blocking agents: No mortality in 40 cases Blocking of beta-adrenergic receptors may be an autolimited phenomenon. Int J Clin Pharmacol Res. 1982;2(3):207–10.
26. Love JN. Beta blocker toxicity after overdose: when do symptoms develop in adults? J Emerg Med. 1994;12(6):799–802.
27. Reth DM, Dawson AH, Epid D, Whyte IM, Buckley NA, Sayer GP. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996;34(3):273–8.
28. Wax P, Erdman A, Chyka P, Keyes D, Caravati EM, Booze L, et al. Beta-blocker ingestion: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2005;43(3):131–46.
29. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984;13(12):1123–31.
30. Azepey P, Boukara N, Richard C, Giudicelli JF. Acute poisoning caused by beta blockers in the adult: Apropos of 7 cases. Ann Cardiol Angeiol (Paris). 1983;32(4):253–8.
31. Gengo FM, Huntlohn L, McHugh WB. Lipid-soluble and water-soluble beta-blockers: Comparison of the central nervous system depressant effect. Arch Intern Med. 1987;147(11):39–43.
32. Lauterbach M. Clinical toxicology of beta-blocker overdose in adults. Basic Clin Pharmacol Toxicol. 2019;125(2):178–86.
33. Lifshitz M, Zucker N, Zaltaizen E. Acute dilated cardiomyopathy and central nervous system toxicity following propranolol intoxication. Pediatr Emerg Care. 1999;15(4):262–3.
34. Cammu G, Geelen P, Baetens P, De Vos J, Demeyer I. Two cases of torsades de pointes caused by sotalol therapy. Resuscitation. 1999;40(1):49–51.
35. Gupta AK, Greller HA, Chan GM, Lee DC, Caraccio T, Mcguigan M, et al. Sotalol induced torsade de points and enhanced elimination with hemodialysis. Clin Toxicol. 2009;47(7):723.

36. Oltmanns G, Schwela H, Kulick B, Knappe J, Haustein KQ, Schmidt H. Acute beta blocker poisoning: Zweischrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete. 1985;40(18):546–51.

37. Vucinic S, Jokovic D, Jovanovic D, Vucinic Z, Todoric V. Factors influencing the degree and outcome of acute beta-blockers poisoning. Vojnosanit Pregl. 2000;57(6):619–23.

38. Hermanns-Clausen M, Sydow A, Desel H. Metoprolol overdoses - Clinical course in relation to ingested dose (German). Intensivmedizin und Notfallmedizin. 2005;42(1):47–52.

39. Forrester MB. Pattern of adult carvedilol ingestions reported to poison control centers. Clin Toxicol. 2009;47(7):746–7.

40. Love JN, Howell JM, Klein-Schwartz W, Litovitz TL. Lack of toxicity from beta-blocker overdose: a retrospective review of poison center data for intentional beta-blocker and/or calcium channel blocker ingestions. Clin Toxicol. 2011;49(6):601.

41. M’Rad A, Blel Y, Essafi F, Fouldhaili N, Ben Slimen A, Brahim N, et al. Prognostic value of plasma concentration of acetylcholine in acute poisoning. Annals of Intensive Care Conference: French Intensive Care Society, International Congress Reanimation. 2016;6(SUPPL. 1).

42. Love JN. Beta-blocker toxicity: a clinical diagnosis. Am J Emerg Med. 1994;12(3):356–7.

43. Flishman W, Jacob H, Eisenberg E, Ribner H. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8. Self-poisoning with beta-receptor blocking agents: recognition and management. Am Heart J. 1979;98(6):798–811.

44. Neuvonen PJ, Elonen E, Tarssanen L. Sotalol intoxication, two patients. Vojnosanit Pregl. 2000;57(6):619–23.

45. Somberg JC, Preston RA, Ranade V, Molnar J. QT prolongation and electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med. 2002;40(6):603–10.

46. Ebis HG, Obersdise U, Brambach U. Intoxication by beta-blockers in children and adolescents (author's transl). Monatsschr Kinderheilkd. 1982;130(5):292–5.

47. Gummel DD. Gresler JB, Brooks DE, Beuhler MC, Rivers LJ, et al. 2018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila). 2019;57(12):420–433.

48. Gummel DD, Mowry JB, Spyker DA, Brooks DE, Osterholler KM, Bannister W. Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol. 2017;55(1):1–203.

49. Johnson NJ, Gaiska DF, Allen SR, Perrone J, DeRoos F. A review of emergency cardiopulmonary bypass for severe poisoning by cardiotoxic drugs. J Med Toxicol. 2013;9(1):54–60.

50. Megabranie B, Deye N, Baud FJ. Extracorporeal life support for acute poisonings with cardiotoxicants (French). Reanimation. 2009;18(S):428–38.

51. Patlanck W, Jelic T. Emergency department management of calcium-channel blocker, beta blocker, and digoxin toxicity. Emerg Med Pract. 2014;16(2):1–19 (quiz 20).

52. Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antedotes and adjunct therapies. Br J Clin Pharmacol. 2016;81(3):453–61.

53. Sjoog GA, Engebren KM. Are vasopressors useful in toxic-induced cardiogenic shock? Clin Toxicol. 2017;55(4):285–304.

54. Dahleb K, Lipman ML, Hildgen P, Roy JJ. Artificial neural network modeling for drug dialyzability prediction. J Pharm Pharmaceut Sci. 2013;16(5):665–75.

55. Heath A, Gabrielsson M, Redgardh CG. Absorption of beta-adrenoceptor antagonists to Amberlite resin. Br J Clin Pharmacol. 1983;15(4):490–2.

56. Pauls A, Grigolet H, von Herrath D, Schafer K. Comparison of drug elimination by current methods of blood purification. Blood Purif. 1984;2(1):14–22.

57. Schneider T, Siegmund W, Franke G, Kraatz G, Schuberth A. The binding of propranolol, dihydralazine and selected metabolites to adsorbent resins for hemoperfusion. Pharmazie. 1986;41(10):742–3.

58. Celardo A, Traina GL, Arboix M, Puigdemont A, Bonati M. Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis. Eur J Drug Metab Pharmacokinet. 1987;12(1):41–8.

59. Traina GL, Celardo A, Arboix M, Bonati M. Experimental model for pharmacokinetic studies during continuous peritoneal dialysis in the rabbit. J Pharmacol Methods. 1986;15(2):133–41.

60. Gvilt PR. General equation for assessing drug removal by extracorporeal devices. J Pharm Sci. 1981;70(3):345–6.

61. Eastwood JB, Curtis JR, Smith RB. Pharmacodynamics of practolol in chronic renal failure. BMJ. 1973;4(5888):320–2.

62. Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Corksena WF, Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther. 1974;16(S Part 1):761–9.

63. Harvenga C, Desager JP, Muschert JM, Tjandramaga YB, Verbeek R, Verberckmoes R. Influence of the hemodialysis on the half-life of practolol in patients with severe renal failure. J Clin Pharmacol. 1975;15(8):9:605–10.

64. Roux A, Aubert P, Guedon J, Flouvat B. Study of atenolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis. Nouv Presse Med. 1975;4(46 Suppl):3228–33.

65. Aubert P, Roux A, Flouvat B, Lucsco M, Caignon M, Guedon J. Pharmacokinetics of atenolol in renal failure. J Urol Nephrol (Paris). 1976;82(9):799–804.

66. B Bianchetti G, Graziani G, Braccaccio D, Morganti A, Leonetti G, Manfrin M, et al. Pharmacokinetics and effects of propranolol in terminal uremic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet. 1976;1(5):373–84.

67. Tjandramaga TB, Verbeek R, Thomas J, Verberckmoes R, Scheper PJ. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol. 1976;3(2):259–65.

68. Lowenthal DT, Pinto JM, Affrime MB, Shirk J, Busby P, Kim KE, et al. Timolol kinetics in chronic renal insufficiency. Clin Pharmacol Ther. 1978;23(5):606–15.

69. Niedermayer W, Seiler KU, Wassermann D. Pharmacokinetics of antihypertensive drugs (atenolol, metoprolol, propranolol and clonidine) and their metabolites during intermittent hemodialysis in humans. Proc Eur Dial Transplant Assoc. 1978;15:607–9.

70. Flouvat B, Decourt S, Potaux L. Pharmacokinetics of propranolol in patients with chronic renal insufficiency undergoing hemodialysis. Therapie. 1979;34(1):63–72.

71. Herrera J, Yukovich RA, Griffith DL. Elimination of nadolol by patients with renal impairment. Br J Clin Pharmacol. 1979;7(Suppl 2):227S–251S.

72. Rosseel MT, Bogaert MG, Christiaens M, Verpooten GA, De Broe ME. Plasma levels of atenolol after haemodialysis in patients with end stage renal disease. Arch Int Pharmacodyn Ther. 1979;239(1):176.

73. Bailey RR, Munn SR, Begg E. The pharmacokinetics of acebutolol in patients with renal functional impairment. Aust N Z J Med. 1980;10(1):124.

74. Megabranie B, Deye N, Baud FJ. Extracorporeal life support for acute poisonings with cardiotoxicants (French). Reanimation. 2009;18(S):428–38.

75. Sjoog GA, Engebren KM. Are vasopressors useful in toxic-induced cardiogenic shock? Clin Toxicol. 2017;55(4):285–304.
81. Schneck DW, Pritchard JF, Gibson TP, Vary JE, Hayes AH Jr. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites. Clin Pharmacol Ther. 1980;27(6):744–55.
82. Seiler R, Schuster KJ, Meyer GJ, Niedermayer W, Wassermann O. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet. 1980;5(2):192–8.
83. Blair AD, Burgess ED, Maxwell BM, Cutler RE. Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther. 1981;29(4):457–63.
84. Dayer P, Glasson P, Gorgia A, Balant L, Fabre J. Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency. Schweizerische medizinische Wochenschrift. 1981;111(49):1915–8.
85. Kirch W, Kohler H, Mutschler E, Schafer M. Pharmacokinetics of atenolol in relation torenal function. Eur J Clin Pharmacol. 1981;19(1):65–71.
86. Bouchet JL, Pocheville M, Alsbach M. Betaxolol pharmacokinetics in chronic renal failure, hemodialysis and CAPD (French). Nephrologie. 1982;5(3):142.
87. Kawasaki T, Ueno M, Uezono K, Abe I, Kawazoe N, Omae T, et al. Blood levels of long-acting propranolol in normal subjects and patients with renal failure. Fukusoku igaku zashi = Hukusoku acta medica. 1983;74(11):737–43.
88. Krause W, Kunte D, Fischer HC. Pharmacokinetics of mepinolol in patients with chronic renal failure. Eur J Clin Pharmacol. 1984;27(4):429–33.
89. Michaels RS, Duchin KL, Akbar S, Meister J, Levin NW. Nadolol in hypertensive patients maintained on long-term hemodialysis: Am Heart J. 1984;108(4 Pt 2):1091–4.
90. Sahahudeen AK, Wilkinson R, McAnish J, Bateman DN, Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Br J Clin Pharmacol. 1984;18(3):457–60.
91. Campese VM, Feinstein EG, Gura V, Mason WD, Massry SG. Pharmacokinetics of atenolol in patients treated with chronic hemodialysis or peritoneal dialysis. J Clin Pharmacol. 1985;25(6):393–5.
92. Halstenson CE, Opsahl JA, Pence TV, Luke DR, Sirgo MA, Plachetka JR, et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther. 1986;40(4):462–8.
93. Payton CD, Fox JG, Pauleau NF, Boulton-Jones JM, Ioannides C, Johnston JG. Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther. 1989;45(3):321–7.
94. Gasparovic V, Milutinovic S, Plavsic F, Jovanovic B. Atenolol and amlodipine combination overdose managed with intermittent peritoneal dialysis. Perit Dial Int. 1991;17(2):207–8.
95. van Ulum SH, van den Merklof LF, Lucassen AM, Wuis EW, Diermont W. Successful haemodialysis in sotalol-induced torsade de points in a CAPD patient—successful treatment with intermittent peritoneal dialysis. Nephrol Dial Transplant. 1997;12(2):311–3.
96. Stein H, Sirotta R, Spipes E, Gronich J, Collins D. Acute hemodialysis for sotalol-induced torsade de points in a patient with progressive renal failure. Nephrol Dial Transplant. 2001;11(2):283–4.
97. Salhanick SD, Wax PM. Treatment of atenolol overdose in a patient with renal failure using serial hemodialysis and hemoperfusion and associated echocardiographic findings. Vet Hum Toxicol. 2000;42(4):224–5.
98. Kolcz J, Pietrzyk J, Januszewska K, Procelewicz M, Mroczek T, Malec E. Acute propranolol intoxication (ASAIO Journal (March/April 1998) 44 (70A)). ASAIO J. 1998;44:70A.
99. Bergl Z, Simecek V. Protracted cardiopulmonary resuscitation in patient intoxicated with lethal dose of beta-blocker Sectral (Czech). Anestesiologie a Reanimation. 2000;51(2):123–4.
100. Bouchard C, Majlesi N, Greller HA, Lee DC, Su MK, Chan GM. Sotalol-induced torsades de points in a patient successfully treated with hemodialysis. Crit Care Med. 1991;19(1):116–8.
101. Krueger M, Achenbach H, Terhaag B, Haase H, Richter K, Oertel R, et al. Detoxication by hemoperfusion. Z Gesamte Inn Med. 1983;8(5):279–86.
102. Anthony T, Jastremski M, Elliott W, Morris G, Prasad H. Charcoal hemoperfusion for the treatment of a combined diltiazem and metoprolol overdose. Ann Emerg Med. 1986;15(11):1344–8.
103. Terhaag B, Gruntert A, Richter K, Dahlmann G, Glaris A. Effectiveness of hemoperfusion in talinolol overdose—a case report. Z Klin Med. 1987;42:1463–8.
104. Sandeep P, Ram R, Sowgandhi N, Nandy SA, Kalyarla DT, Kumar BS, et al. Atenolol and amlopidine combination overdose managed with
continuous venovenous hemodiafiltration: a case report. Indian J Nephrol. 2014;24(5):327–9.

128. Heise CW, Bieutler D, Bosak A, Orme G, Loli A, Graeme K. Massive ateno-
lol, isoprenaline, and chloralhydrate overdose treated with endoscopic decon
tamination, hemodialysis, impella percutaneous left ventricular assist device, and ECMO. J Med Toxicol. 2015;11(1):110–4.

129. Seegobin K, Maharaj S, Deosaran A, Reddy P. Severe beta blocker and
calcium channel blocker overdose: Role of high dose insulin. Am J Emerg Med. 2018;36(4):736 e5–e6.

130. Chen LW, Mao DR, Chen YS. Extracorporeal life support: the final “antidote” for massive propranolol overdose. Hong Kong J Emerg Med. 2019;26(2):118–23.

131. Talbert RL, Wong YY, Duncan DB. Propranolol plasma concentrations
and phammasphere. Drug Intell Clin Pharm. 1981;15(12):993–6.

132. Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM,
et al. Guidelines for reporting case studies on extracorporeal treatments in
poisonings: methodology. Semin Dial. 2014;27(4):407–14.

133. Bouchard J, Lavergne V, Roberts DM, Cormier M, Morissette G, Ghan-
noum M. Availability and cost of extracorporeal treatments for poison-
ings and other emergency indications: a worldwide survey. Nephrol Dial Transplant. 2017;32(4):699–706.

134. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should
know about the QT interval. JAMA. 2003;289(16):2120–7.

135. Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson JL, et al.
“Antidote” for massive propranolol overdose. Hong Kong J Emerg Med. 2016;23(2):357–9.

136. Bouchard J, Roberts DM, Roy L, Ouellet G, Decker BS, Mueller BA, et al.
Decourt S, Roux A, Baglin A, Aubert P, Prinseau J, Flouvat B. Influence of
protein binding on dialysis clearance of several beta-blocking agents in
chronically hemodilated patients. Therapie. 1982;37(6):635–40.

137. Mason WD, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute
bioavailability of atenolol. Clin Pharmacol Ther. 1979;25(4):408–15.

138. McAinsh J, Holmes BF, Smith S, Hood D, Warren D. Atenolol kinetics in
renal failure. Clin Pharmacol Ther. 1980;28(3):302–9.

139. Rubin PC, Scott PJ, McLean K, Pearson A, Ross D, Reid JL. Ateno-
lol disposition in young and elderly subjects. Br J Clin Pharmacol. 1982;13(2):235–7.

140. Kirch W, Schafer-Korting M, Mutschler E, Hohnhaus EE, Braun W. Clinical
experience with atenolol in patients with chronic liver disease. J Clin Pharmacol. 1983;23(4):171–7.

141. Buck ML, Wiest D, Gillette PC, Trippel D, Krull J, O’Neal W. Pharmacoki-
netics and pharmacodynamics of atenolol in children. Clin Pharmacol Ther. 1989(46):629–33.

142. Bovet P, Maltais F, Gervais A, Bouvet G, Langlois G. Severe atenolol
overdose treated with endoscopic hemodialysis and ECMO. J Med Toxicol. 2015;11(1):110–4.
221. Janku I, Perlik F, Traczykova M, Brodanova M. Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects. Eur J Clin Pharmacol. 1992;42(2):337–40.

222. Appelgren C, Borg KO, Elofsson R, Johansson KA. Binding of adrenergic beta-receptor antagonists to human serum albumin. Acta Pharm Suec. 1974;11(4):325–32.

223. Regardh CG, Borg KO, Johansson R, Johnsson G, Palmer L. Pharmacokinetic studies on the selective beta1-receptor antagonist metipranolol in man. J Pharmacokin Biopharm. 1974;2(4):367–464.

224. Regardh CG, Jordo L, Erik M, Lundborg P, Olsson R, Ronn O. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet. 1981;6(5):375–88.

225. Regardh CG, Landahl S, Larsson M, Lundborg P, Steen B, Hoffmann KJ, et al. Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur J Clin Pharmacol. 1983;24(2):221–6.

226. Richard J, Cardot JM, Godbillon J. Inter- and intra-subject variability of metoprolol kinetics after intravenous administration. Eur J Drug Metab Pharmacokinet. 1994;19(2):157–62.

227. Schaaf LJ, Campbell SC, Mayersohn MB, Vagedes T, Perrier DG. Influence of smoking and gender on the disposition kinetics of metoprolol. Eur J Clin Pharmacol. 1987;33(4):355–61.

228. Jordo L, Attman PO, Aurell M, Johansson L, Johnsson G, Regardh CG. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980;5(2):169–80.

229. Regardh CG, Johnsson G, Jordo L, Solvell L. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):45–58.

230. Regardh CG, Johnsson G, Jordo L, Lungborg P, Persson BA, Ronn O. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J Cardiovasc Pharmacol. 1980;2(6):715–23.

231. Patel L, Johnson A, Turner P. Nadolol binding to human serum proteins. Dreyfuss J, Brannick LJ, Vukovich RA, Shaw JM, Willard DA. Metabolic and pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. Br J Clin Pharmacol. 1985;19(Suppl 2):163S–S169.

232. Riess W, Huerzeler H, Raschdorf F. The metabolites of oxprenolol (Traslo- cor) in man. Xenobiotica; the fate of foreign compounds in biological systems. 1974;4(6):365–73.

233. Dayer P, Glasson P, Balant L, Stibreni R, Fabre FJ. Differential consequences of renal failure on the pharmacokinetics of oxprenolol and its main metabolite. Eur J Drug Metab Pharmacokinet. 1983;8(2):181–8.

234. Rigby JW, Scott AK, Hawksworth GM, Petrie JC. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Br J Clin Pharmacol. 1985;20(4):327–31.

235. Laethem ME, Lefebvre RA, Belpaire FM, Vanden EE, Bogaert MJ. Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans. Clin Pharmacol Ther. 1995;57(4):419–24.

236. Mason WD, Winer N. Pharmacokinetics of oxprenolol in normal subjects. Clin Pharmacol Ther. 1976;20(4):401–12.

237. Bradbrook ID, John VA, Morrison PJ, Rogers HJ, Spector RG. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. Br J Clin Pharmacol. 1985;19(Suppl 2):163S–S169.

238. Briciu C, Neag M, Muntean D, Bocsan C, Buzoianu A, Antonescu O, et al. Penbutolol: pharmacokinetics, effect on exercise tachycardia, and haemodynamic effects during exercise in man. Eur J Clin Pharmacol. 1993;44(2):171–6.

239. Gottschalk R, Sistovaris N. Protein binding studies of furosemide and penbutolol. Arzneimittelforschung. 1985;35(6):899–902.

240. Aguirre C, Rodriguez-Sasian JM, Calvo R. Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents. Cancer Chemother Pharmacol. 1994;39(1):86–8.

241. Laethem ME, Lefebvre RA, Belpaire FM, Vanhoe HL, Bogaert MJ. Stereoselective pharmacokinetics of oxprenolol and its glucuronides in humans. Clin Pharmacol Ther. 1995;57(4):419–24.

242. Spahn H, Hajdu P, Rüscheneder DM, Neubauer E, Altmeyer P, et al. Pharmacokinetics of penbutolol and its metabolites in man. Clin Pharmacol Ther. 1985;37(2):183–91.

243. Bernard N, Cuisinard G, Pozet N, Zech PY, Sassaard J. Pharmacokinetics and pharmacodynamic properties of penbutolol in normal and obese subjects. Eur J Clin Pharmacol. 1988;33(6):625–8.

244. Spahn H, Kirch W, Hajdu P, Mutschler E, Ohnhaus EE. Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine. Eur J Clin Pharmacol. 1986;29(5):555–60.

245. Broekmeier D, Hajdu P, Henke W, Mutschler E, Palm D, Rupp W, et al. Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioisotopic binding. Eur J Clin Pharmacol. 1977;12(2):135–40.

246. Laport CD, Hensell JK, Bromley PA, Torres J, Vanderbeke O, Single and divided doses of penbutolol. Clin Pharmacol Ther. 1979;25(5 Pt 1):528–35.

247. Ochs HR, Hajdu P, Greenblatt DJ. Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance. Klin Wochenschr. 1986;64(14):636–41.

248. Spahn H, Kirch W, Hajdu P, Mutschler E, Ohnhaus EE. Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine. Eur J Clin Pharmacol. 1986;29(5):555–60.

249. Broekmeier D, Hajdu P, Henke W, Mutschler E, Palm D, Rupp W, et al. Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioisotopic binding. Eur J Clin Pharmacol. 1977;12(2):135–40.

250. Muller FO, Hundt HK, Bromley PA, Torres J, Vanderbeke O, Single and divided doses of penbutolol. Clin Pharmacol Ther. 1979;25(5 Pt 1):528–35.

251. Vedin JA, Wilhelmsen C, Maas L, Peterson LE. Pharmacokinetic and pharmacodynamic study of oral and intravenous penbutolol. Eur J Clin Pharmacol. 1983;25(4):529–34.

252. Lu X, Lea Y, He L, Liu W, Li M, Ruan L, et al. No influence of CYP2D6*10 genotype and phenotype on the pharmacokinetics of penbutolol in healthy Chinese subjects. J Clin Pharmacol Ther. 2015;40(5):561–6.

253. Galeazzi RL, Gugger M, Weidmann P. Beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man. Kidney Int. 1979;15(6):661–8.

254. Gulger R, Herold W, Dengler HJ. Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol. 1974;7(1):17–24.
265. Lavene D, Weiss YA, Safar ME, Loria Y, Agerus N, Georges D, et al. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. J Clin Pharmacol. 1977;17(8–9):501–8.

266. Juma F.D. Pharmacokinetics of pindolol in Kenyan Africans. Eur J Clin Pharmacol. 1983;25(3):425–6.

267. Chau NP, Weiss YA, Safar ME, Lavene DE, Georges DR, Milliez PL. Pindolol availability in hypertensive patients with normal and impaired renal function. Clin Pharmacol Ther. 1977;22(5 Pt 1):505–10.

268. Guerret M, Cheymol G, Aubry JP, Cheymol A, Lavene D, Kiechel JR. Estimation of the absolute oral bioavailability of pindolol by two analytical methods. Eur J Clin Pharmacol. 1983;25(3):357–9.

269. Stone WJ, Vallerie T. Massive propranolol metabolite retention during maintenance hemodialysis. Clin Pharmacol Ther. 1980;28(4):449–55.

270. Bodem G, Chidsey CA. Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clin Pharmacol Ther. 1973;14(1):26–9.

271. Bodem G, Grieser H, Eichelbaum M, Gugler R. Pharmacokinetics of practolol in renal failure. Eur J Clin Pharmacol. 1974;7(4):249–52.

272. Kaye CM, Kumana CR, Franklin DA, Baker LR. A study of practolol elimination in all grades of chronic renal failure. Int J Clin Pharmacol Biopharm. 1975;12(1–2):83–8.

273. Titstone WJ, Semple PF, Boyle JA. Proceedings: The renal clearance of practolol in man. J Pharm Pharmacol. 1974;26(Suppl):66P–96P.

274. Guidicelli JF, Fillérent JP, Boissier JR. Beta-adrenergic activity compared in vitro and in vivo and protein fixation. J Pharmacol. 1973:129–36.

275. Graffner C, Hoffmann KJ, Johnsson G, Lundborg P, Ronn O. Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure. Acta Med Scand Suppl. 1982,659:89–98.

276. Dahlstrom U, Graffner C, Jonsson U, Hoffmann KJ, Karlsson E, Lagerborg P, Ronn O, Graffner C, Johnsson G, Jordo L, Lundborg P, Svensson L. Ronn O, Fellenius E, Graffner C, Johnsson G, Lundborg P, Svensson L. Pharmacokinetics of prenalterol in cardiac failure. Eur J Clin Pharmacol. 1983;34(6):749–57.

277. Arends BG, Bohm RO, van Kemenade JE, Rahn KH, van Baak MA. Influence of physical exercise on the pharmacokinetics of propranolol. Eur J Clin Pharmacol. 1986;31(3):375–7.

278. Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol. 1986;21(5):529–32.

279. Olanoff LS, Walle T, Cowart TD, Walle UK, Oexmann MJ, Conradi EC. Stereoselective pharmacokinetics of intravenous dl-propranolol in black and white volunteers. J Cardiovasc Pharmacol. 1985;7(2):409–10.

280. Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther. 1984;35(6):755–61.

281. Venter CP, Joubert PH, Strydom WJ. Comparative pharmacokinetics of intravenous propranolol in black and white volunteers. J Cardiovasc Pharmacol. 1985;7(2):409–10.

282. Wilson TW, Firor WB, Johnson GE, Holmes GI, Tsianco MC, Huber PB, et al. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther. 1982;32(6):676–85.

283. Chidsey CA, Morselli P, Bianchetti G, Morganti A, Leonetti G, Zanchetti A. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation. 1975;52(2):313–8.

284. Olanoff LS, Walle T, Cowart TD, Walle UK, Derrmann MJ, Conradi EC. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther. 1986;40(4):408–14.

285. Arentz S, Arntz M, Pfeffer M, Tikkannen R, Vallinkoski S, Sundquist H. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol (Copenh). 1976;39(1):118–28.

286. Poirier JM, Jaillen P, Lecocq B, Lecocq V, Ferry A, Cheymol G. The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. Eur J Clin Pharmacol. 1990;38(6):579–82.

287. Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol. 1997;37(9):799–809.

288. Tscholakian V, Mardikian P, Righi G, et al. Variations of sotalol kinetics in renal insufficiency. Int J Clin Pharmacol Ther Toxicol. 1989;27(10):486–9.

289. Sundquist H, Arentz S, Simon A, Reich JW. Comparative bioavailability and pharmacokinetics of sotalol administered alone and in combination with hydrochlorothiazide. J Clin Pharmacol. 1979;19(8–9 Pt 2):557–64.

290. Uematsu T, Kanamaru M, Nakashima N. Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers. J Pharm Pharmacol. 1994;46(7):600–5.

291. Blair AD, Cutlere RE, Lam FY. Pharmacokinetics of sotalol in humans with normal and varying degrees of renal function. Clin Res. 1980;28(1):68A.

292. Dumas M, d’Arfis P, Besancenot JF, Chaudot-Notoueau V, Chaplin JM, Risle G, et al. Variations of sotalol kinetics in renal insufficiency. Int J Clin Pharmacol Ther Toxicol. 1989;27(10):486–9.

293. Sundquist HK, Arentz S, Forström J, Kasanen A. Serum levels and half-life of sotalol in chronic renal failure. Ann Clin Res. 1975;7(6):442–6.

294. Trausch B, Oertel R, Richter K, Grammatke T. Disposition and bioavailability of the beta 1-adrenergic antagonist talinolol in man. Biopharm Drug Dispos. 1995;16(5):403–14.
312. Haustein KO, Fritzschke K. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent. Int J Clin Pharmacol Ther Toxicol. 1981;19(9):392–5.
313. Terhaag B, Palm U, Sahre H, Richter K, Oertel R. Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. Eur J Clin Pharmacol. 1992;42(4):461–2.
314. Ishizaki T, Tawara K, Oyama Y, Nakaya H. Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. J Clin Pharmacol. 1978;18(11–12):511–8.
315. Else OF, Sorenson H, Edwards IR. Plasma timolol levels after oral and intravenous administration. Eur J Clin Pharmacol. 1978;14(6):431–4.
316. Vedin JA, Kristansson JK, Wilhelmsson CE. Pharmacokinetics of intravenous timolol in patients with acute myocardial infarction and in healthy volunteers. Eur J Clin Pharmacol. 1982;23(1):43–7.
317. El-Rashidy R. Estimation of the systemic bioavailability of timolol in man. Biopharm Drug Dispos. 1981;2(2):197–202.
318. Faulkner JK, Stephe DA, Walden R. Pharmacokinetic and pharmacological studies with timolol in man. Br J Clin Pharmacol. 1975;2(5):423–8.
319. Routledge PA, Davies DM, Rawlins MD. Pharmacokinetics of timolol in the treatment of hypertension. Eur J Clin Pharmacol. 1977;12(3):171–4.
320. Balant L, Gorgia A, Marmy A, Tschopp JM. [Clearance concept applied to pharmacokinetics: 2. Experience with timolol (beta-blocking agent) in renal insufficiency (author's transl)]. Nephrologie. 1980;1(4):177–82.
321. Williams HA, Henke D, Elamin MEMO, Sandilands EA, Thomas SHL, Thompson JP, et al. Can poisons centre data inform safer prescribing? A pilot review of propranolol exposures reported to the UK National Poisons Information Service (NPIS). Clin Toxicol. 2019;57(6):453.
322. Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. Cochrane Database Syst Rev. 2015;1:CD006962.
323. Parienti JJ, Mongardon N, Megarbane B, Mira JP, Kalfon P, Gros A, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015;373(13):1220–9.
324. Shin HJ, Na HS, Koh WJ, Ro YJ, Lee JM, Choi YJ, et al. Complications in internal jugular vs subclavian ultrasound-guided central venous catheterization: a comparative randomized trial. Intensive Care Med. 2019;45(7):968–76.
325. Bjorkander M, Bentzer P, Schott U, Broman ME, Kander T. Mechanical complications of central venous catheter insertions: A retrospective multicenter study of incidence and risks. Acta Anaesthesiol Scand. 2019;63(1):61–8.
326. Wong B, Zimmerman D, Reintjes F, Courtney M, Klarenbach S, Dowling G, et al. Procedure-related serious adverse events among home hemodialysis patients: a quality assurance perspective. Am J Kidney Dis. 2014;63(2):295–8.
327. Tennakore KK, d’Gama C, Faratro R, Fung S, Wong E, Chan CT. Adverse technical events in home hemodialysis. Am J Kidney Dis. 2015;65(1):116–21.
328. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817–27.
329. Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion. 1989;29(2):124–7.
330. Yang X, Xin S, Zhang Y, Li T. Early hemoperfusion for emergency treatment of carbamazepine poisoning. Am J Emerg Med. 2018;36(6):926–30.
331. Shannon MW. Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Acad Emerg Med. 1997;4(7):674–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.